Evidence map›Paper›PMID 40956872›Full record

ArticleMolecular oncology2025

Only the strong survive: therapeutic selective pressure drives medulloblastoma leptomeningeal metastasis.

Francis Y He, Adrienne Boire

Abstract read
In one paragraph

Article in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Francis Y HeNeuroscience Program, Graduate School of Biomedical Science, Weill Cornell Medicine, New York, USA.
Adrienne BoireHuman Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA.ORCID 0000-0002-9029-1248

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748NCI NIH HHS P30CA008748-59
6 · The paper itself

Abstract

Medulloblastoma (MB) is the most common malignant tumor in the central nervous system in childhood and regularly metastasizes to the leptomeninges following radiation therapy. Using patient-derived medulloblastoma models and genetically engineered mouse models, Nör et al. observed enhanced inflammation and infiltration of myeloid cells within the brain following irradiation. The authors identified inflammatory cytokines and the resulting breakdown of blood-brain barriers as the main culprits of MB leptomeningeal metastasis. This study demonstrated that targeting inflammation through the use of dexamethasone effectively reduced systemic inflammatory cytokines and the resulting radiation-induced leptomeningeal metastasis.

Indexed as

Cerebellar NeoplasmsMedulloblastomaMeningeal NeoplasmsAnimalsCytokinesDexamethasoneHumansMiceCytokinesDexamethasoneleptomeningeal metastasismedulloblastomaradiation therapy

Identifiers

PMID40956872
PMCPMC12515700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.